DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Clinical Trial Comparing the Efficacy and Safety of DA-3803 and Ovidrel

Information source: Dong-A ST Co., Ltd.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hyperovulation Induction for Assisted Reproduction Treatment

Intervention: r-hCG (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Dong-A ST Co., Ltd.

Official(s) and/or principal investigator(s):
TaeGi Yoon, MD, Study Chair, Affiliation: Cha Medical school Gangnam-Cha hospital
DongHee Choi, MD, Principal Investigator, Affiliation: Cha Medical school Boondang-Cha hospital
MiKyoung Goong, MD, Principal Investigator, Affiliation: Kwandong university medical school Cheil hospital

Summary

The purpose of this study is to compare the efficacy and safety of DA-3803(r-hCG) and Ovidrel for inducting final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment

Clinical Details

Official title: Phase III Clinical Trial Comparing the Efficacy and Safety of DA-3803(Recombinant Human Chorionic Gonadotrophin) and Ovidrel for Inducting Final Follicular Maturation and Early Luteinization in Women Undergoing Ovulation

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: the efficacy and safety of DA-3803(r-hCG)

Secondary outcome: the efficacy of DA-3803(r-hCG)

Detailed description: This is an single-blind, randomized, comparative multicentric, phase III study to evaluate the safety and efficacy of DA-3803(r-hCG) in comparison with Ovidrel in the induction of final follicle maturation and early luteinization in 180 Korean female subjects undergoing superovulation. The study is organized on an outpatient basis in subjects undergoing assisted reproductive technologies (ART). The subjects are randomized into 2 groups. One group receive DA-3803(r-hCG) 250mcg and the other group receive Ovidrel®(r-hCG)250mcg. Each subject in both groups receives a single injection of hCG when the follicular development was judged to be adequate. Oocytes are retrieved 34-38 hours after r-hCG injection and fertilized in vitro. Not more than 4 embryos are to be replaced. Progesterone is administered daily according to center's normal practice, starting after the oocyte pick up and continuing until appropriate time. The subject is followed up and the treatment outcome (negative pregnancy test or pregnancy) is recorded.

Eligibility

Minimum age: 20 Years. Maximum age: 38 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Infertility regular ovulatory menstrual cycles : 25~35days

- BMI<=30kg/m2

- Early follicular phase serum levels are normal : FSH, LH, prolactin, testosterone

- Both ovaries present and clinically normal uterine cavity

- < 3 previous ART cycles, no ART cycles for 2 menstrual cycles

- semen analysis and ART are possible

- informed couple consent

Exclusion Criteria:

- With a poor response to gonadotrophin stimulation, such as ≤3 oocytes collected in

any previous ART cycle

- Had previous severe ovarian hyperstimulation syndrome(OHSS)

- Polycystic ovarian syndrome(PCOS)

- Extra-uterine pregnancy within the last 3 months

- A clinically significant uncontrolled endocrine diseases, chronic cardiovascular

disorders, hepatic, pulmonary and renal diseases

- Known allergy,hypersensitivity or contraindication to FSH, hCG, progesterone and GnRH

antagonists

- medication with human gonadotrophin preparations(FSH, LH, hCG) within 2 months

- participation in another clinical trial within 1 month

Locations and Contacts

Cha Medical school Gangnam-Cha hospital, Seoul, Korea, Republic of

Kwandong university medical school Cheil hospital, Seoul, Korea, Republic of

Cha Medical school Boondang-Cha hospital, Seongnam, Gyeong-Gi Do, Korea, Republic of

Additional Information

Starting date: February 2012
Last updated: August 12, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017